Dexcom (DXCM) Gains from Investment Securities (2010 - 2026)

Dexcom (DXCM) has 16 years of Gains from Investment Securities data on file, last reported at $1.5 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $1.5 million, up 36.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.6 million (down 62.38% YoY), and the FY2025 annual result was $19.2 million, down 60.57% from the prior year.
• Gains from Investment Securities declined to $1.5 million in Q1 2026 per DXCM's latest filing, from $17.8 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $36.9 million in Q4 2024 and troughed at -$46.8 million in Q4 2022.
• A 5-year average of $3.2 million and a median of $1.5 million in 2026 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities slumped 360.0% in 2022, then jumped 688.89% in 2023.
• A 5-year view of Gains from Investment Securities shows it stood at -$46.8 million in 2022, then jumped by 38.46% to -$28.8 million in 2023, then surged by 228.12% to $36.9 million in 2024, then tumbled by 51.76% to $17.8 million in 2025, then sank by 91.57% to $1.5 million in 2026.
• Business Quant data shows DXCM's Gains from Investment Securities at $1.5 million in Q1 2026, $17.8 million in Q4 2025, and $900000.0 in Q3 2025.